Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pelthos Therapeutics Inc (PTHS)

Pelthos Therapeutics Inc (PTHS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,288
  • Shares Outstanding, K 3,236
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,960 K
  • EBIT $ -22 M
  • EBITDA $ -21 M
  • 60-Month Beta 4.00
  • Price/Sales 4.03
  • Price/Cash Flow N/A
  • Price/Book 1.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.63
  • Number of Estimates 3
  • High Estimate -1.44
  • Low Estimate -4.96
  • Prior Year -3.20
  • Growth Rate Est. (year over year) -13.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.19 +32.82%
on 02/17/26
27.00 -10.52%
on 02/27/26
-1.14 (-4.51%)
since 02/02/26
3-Month
18.19 +32.82%
on 02/17/26
31.62 -23.59%
on 12/31/25
-0.98 (-3.90%)
since 12/02/25
52-Week
9.00 +168.44%
on 06/02/25
54.29 -55.50%
on 07/07/25
+3.66 (+17.85%)
since 02/28/25

Most Recent Stories

More News
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 24.16 (-8.35%)
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos...

PTHS : 24.16 (-8.35%)
HRZN : 6.06 (+1.68%)
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

DURHAM, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 24.16 (-8.35%)
HRZN : 6.06 (+1.68%)
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

Acquisition adds complementary asset to the Pelthos commercial portfolio Xeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients...

PTHS : 24.16 (-8.35%)
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn

DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 24.16 (-8.35%)
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new...

PTHS : 24.16 (-8.35%)
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 24.16 (-8.35%)
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results

Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1 million...

PTHS : 24.16 (-8.35%)
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™ Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in...

PTHS : 24.16 (-8.35%)
Pelthos Therapeutics Launches Zelsuvmi for Skin Condition

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pelthos Therapeutics...

PTHS : 24.16 (-8.35%)

Business Summary

Pelthos Therapeutics is a biopharmaceutical company. Its lead product includes ZELSUVMI(TM) topical gel. Pelthos Therapeutics, formerly known as Channel Therapeutics Corporation, is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 27.73
2nd Resistance Point 27.01
1st Resistance Point 25.59
Last Price 24.16
1st Support Level 23.45
2nd Support Level 22.73
3rd Support Level 21.31

See More

52-Week High 54.29
Fibonacci 61.8% 36.99
Fibonacci 50% 31.65
Fibonacci 38.2% 26.30
Last Price 24.16
52-Week Low 9.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar